Immunomodulatory trispecific t cell engager fusion proteins
AssigneeZymeworks BC Inc.
InventorsSurjit Bhimarao Dixit, Eric ESCOBAR-CABRERA, Florian Heinkel, Anna Von Rossum, Harsh Pratap, Maya Poffenberger, Chayne L. Piscitelli, Meghan Marie Verstraete
Life of this patent
Estimating the term…
Abstract
The present disclosure provides fusion proteins with a multifunctional biologic design for programmed target engagement. In certain embodiments, the fusion proteins described herein provide for concurrent T cell and target antigen engagement and immune checkpoint targeting.
Claims75
A trispecific fusion protein comprising:
- (i) a first binding domain capable of binding CD3 on the surface of a cytotoxic effector cell;
- (ii) a second binding domain capable of binding a tumor associated antigen (TAA) on the surface of a tumor cell;
- (iii) a third binding domain capable of binding PD-L1 on the surface of a tumor cell;
- and
- (iv) a scaffold,
- wherein the first binding domain, the second binding domain and the third binding domain are operably linked to the scaffold.
(canceled)
(canceled)
(canceled)
(canceled)
A trispecific fusion protein comprising:
- (i) a first binding domain capable of binding CD3 on the surface of a cytotoxic effector cell, wherein the first binding domain is a Fab domain;
- (ii) a second binding domain capable of binding a tumor-associated antigen (TAA) on the surface of a tumor cell;
- (iii) a third binding domain capable of binding PD-L1 on the surface of a tumor cell;
- and
- (iv) a scaffold,
- wherein the first binding domain, the second binding domain and the third binding domain are operably linked to the scaffold, and
- wherein the third binding domain is linked to (i) the N- or C-terminus of the light chain of the Fab domain, (ii) the second binding domain, or (iii) the scaffold.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A tetravalent and trispecific fusion protein comprising:
- (i) a first binding domain capable of binding CD3 on the surface of a cytotoxic effector cell;
- (ii) a second binding domain and a third binding domain capable of binding a tumor-associated antigen (TAA) on the surface of a tumor cell;
- (iii) a fourth binding domain capable of binding PD-L1 on the surface of a tumor cell;
- and
- (iv) a scaffold,
- wherein the first binding domain, the second binding domain, the third binding domain and the fourth binding domain are operably linked to the scaffold.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.